Sugi Predict

Sugi Predict / Compounds / SCHEMBL4979769

SCHEMBL4979769

SCHEMBL4979769

O=C(Nc1cccc(OC(F)(F)F)c1)c1ccccc1NCc1ccncc1

nearest known ligand 0.73

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ KDR P35968 12/20 0.73
▸ FLT1 P17948 11/20 0.73
▸ KIT P10721 3/20 0.73
▸ ABL1 P00519 2/20 0.73
▸ CSF1R P07333 2/20 0.73
▸ PDGFRB P09619 2/20 0.73
▸ FLT4 P35916 2/20 0.73
▸ EGFR P00533 1/20 0.73
▸ NAMPT P43490 1/20 0.62
▸ RXFP1 Q9HBX9 2/20 0.60
▸ BRAF P15056 1/20 0.58
▸ IGF1R P08069 1/20 0.57
▸ FGFR1 P11362 1/20 0.57
▸ TEK Q02763 1/20 0.57
▸ KDM5A P29375 1/20 0.54
▸ KDM4C Q9H3R0 1/20 0.54
▸ KDM5B Q9UGL1 1/20 0.54
▸ P2RX1 P51575 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4980248 0.89 KDR (0.74) KDRFLT1KITABL1CSF1R
SCHEMBL4976103 0.84 KDR (1.00) KDRFLT1KITABL1CSF1R
SCHEMBL29356168 0.84 KDR (1.00) KDRFLT1KITABL1CSF1R
SCHEMBL1714730 0.83 KDM5A (0.56) KDRFLT1KITABL1CSF1R
SCHEMBL4977683 0.81 KDR (0.71) KDRFLT1KITABL1CSF1R
SCHEMBL4022500 0.81 KDR (0.60) KDRFLT1KITABL1CSF1R
SCHEMBL4982167 0.81 KDR (0.71) KDRFLT1KITABL1CSF1R
SCHEMBL4976779 0.81 KDR (0.71) KDRFLT1KITABL1CSF1R
SCHEMBL4978310 0.81 KDR (0.71) KDRFLT1KITABL1CSF1R
SCHEMBL4982146 0.81 KDR (0.71) KDRFLT1KITABL1CSF1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040198782-A1 N-aryl (THIO) anthranilic acid amide derivatives, their preparation and their use as VEGF receptor tyrosine kinase inhibitors ALTMANN KARL-HEINZ (CH) 2004-10-07 — — US claimed
US-20030064992-A1 N-aryl (thio) anthranilic acid amide derivatives, their preparation and their use as VEGF receptor tyrosine kinase inhibitors ALTMANN KARL-HEINZ (CH) 2003-04-03 — — US claimed
US-6448277-B2 ANTITUOR AGENTS, ANTICARCINOGENIC AGENTS NOVARTIS AG (CH) 2002-09-10 — — US claimed
CN-1331680-A N-aryl (thio) anthranilic acid amide derivatives, their prepn. and their use as VEGF receptor tyrosine kinase inhibitors NOVARTIS AG (CH) 2002-01-16 — — CN claimed
US-20080085902-A1 Combination Of A Vegf Receptor Inhibitor Or With A Chemotherapeutic Agent BOLD GUIDO 2008-04-10 — — US disclosed
US-20060074112-A1 N-aryl (thio) anthranilic acid amide derivatives, their preparation and their use as VEGF receptor tyrosine kinase inhibitors ALTMANN KARL-HEINZ 2006-04-06 — — US disclosed
US-7002022-B2 N-Aryl (thio) anthranilic acid amide derivatives, their preparation and their use as VEGF NOVARTIS AG (CH) 2006-02-21 — — US disclosed
US-6878720-B2 VEGF receptor tyrosine kinase inhibitors NOVARTIS AG (CH) 2005-04-12 — — US disclosed
US-20040198782-A1 N-aryl (THIO) anthranilic acid amide derivatives, their preparation and their use as VEGF receptor tyrosine kinase inhibitors ALTMANN KARL-HEINZ (CH) 2004-10-07 — — US disclosed
CN-1152014-C N-aryl (thio) anthranilic acid amide derivatives, their prepn. and their use as VEGF receptor tyrosine kinase inhibitors ��˹��ŵ�� 2004-06-02 — — CN disclosed
US-20030064992-A1 N-aryl (thio) anthranilic acid amide derivatives, their preparation and their use as VEGF receptor tyrosine kinase inhibitors ALTMANN KARL-HEINZ (CH) 2003-04-03 — — US disclosed
US-20020019414-A1 N-aryl(thio)anthranilic acid amide derivatives, their preparation and their use as VEGF receptor tyrosine kinase inhibitors NOVARTIS AG (CH) 2002-02-14 — — US disclosed
CN-1331680-A N-aryl (thio) anthranilic acid amide derivatives, their prepn. and their use as VEGF receptor tyrosine kinase inhibitors NOVARTIS AG (CH) 2002-01-16 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080085902-A1 Combination Of A Vegf Receptor Inhibitor Or With A Chemotherapeutic Agent VEGFA, FLT1, FLT4 KDR 4/4885FLT1 2/4885KIT 95/4885
US-20030064992-A1 N-aryl (thio) anthranilic acid amide derivatives, their preparation and their use as VEGF receptor tyrosine kinase inhibitors AXL, TYRO3, NR2E3 KDR 4/4885FLT1 6/4885KIT 1200/4885
US-20060074112-A1 N-aryl (thio) anthranilic acid amide derivatives, their preparation and their use as VEGF receptor tyrosine kinase inhibitors NR2E3, AXL, FLT1 KDR 6/4885FLT1 3/4885KIT 1240/4885
US-20020019414-A1 N-aryl(thio)anthranilic acid amide derivatives, their preparation and their use as VEGF receptor tyrosine kinase inhibitors AXL, TYRO3, KDR KDR 3/4885FLT1 6/4885KIT 1055/4885
US-20040198782-A1 N-aryl (THIO) anthranilic acid amide derivatives, their preparation and their use as VEGF receptor tyrosine kinase inhibitors AXL, TYRO3, NR2E3 KDR 4/4885FLT1 6/4885KIT 1176/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.